OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Melinda Irwin on Impact of Exercise on Survivors' Quality of Life

June 15th 2015

Melinda Liggett Irwin, PhD, MPH, associate professor of epidemiology (chronic diseases), Yale School of Public Health, co-program leader, Cancer Prevention and Control Research Program, Yale Cancer Center, discusses the impact of the LIVESTRONG at the YMCA Program on survivors' fitness, physical activity, and quality of life.

Holli Dilks on Molecular Profiling

June 12th 2015

Holli Dilks, PhD, Director, Personalized Medicine Operations Sarah Cannon Research Institute, discusses molecular profiling.

Dr. Goldberg on PD-1 Blockade in Tumors with Mismatch Repair Deficiency

June 12th 2015

Richard Goldberg, MD, Ohio State University Comprehensive Cancer Center-James Cancer Hospital, discusses PD-1 blockade in tumors with mismatch repair deficiency.

Dr. Brahmer on Impact of CheckMate-057 in NSCLC

June 11th 2015

Julie R. Brahmer, MD, interim director, Sidney Kimmel Comprehensive Cancer Center, associate professor of oncology, Johns Hopkins Medicine, discusses how the CheckMate-057 trial could impact the treatment of non-small cell lung cancer (NSCLC).

Dr. Jurcic on Lintuzumab and Low-Dose Cytarabine for AML

June 11th 2015

Joseph Jurcic, MD, professor of Clinical Medicine, director of the Hematologic Malignancies Section of the Hematology/Oncology Division, Columbia University Medical Center, discusses a phase I trial of lintuzumab and low-dose cytarabine (LDAC) in older patients with untreated acute myeloid leukemia (AML).

Dr. Saad Usmani on Daratumumab Monotherapy for Multiple Myeloma

June 11th 2015

Saad Z. Usmani, MD, director, Clinical Research Hematologic Malignancies, director, Plasma Cell Disorders, Levine Cancer Institute/Carolinas Healthcare System, discusses daratumumab for patients with relapsed/refractory multiple myeloma.

Dr. Dalgleish on IMM-101 With Gemcitabine for Pancreatic Cancer

June 10th 2015

Angus Dalgleish, MD, FRCP, FRACP, FRCPath, FMedSci, professor, Department of Oncology, St. George's, University of London, discusses a study that examined the combination of an immunomodulator with gemcitabine in patients with pancreatic cancer.

Dr. Kari Wisinski on Palbociclib for Metastatic Breast Cancer

June 10th 2015

Kari Wisinski, MD, medical oncologist with University Of Wisconsin Health and the University of Wisconsin Carbone Cancer Center, discusses the use of palbociclib for patients with ER-positive and HER2-negative breast cancer.

Dr. Jerome Kim on Geriatric Assessment Tool for Older Patients With Cancer

June 9th 2015

Jerome G. Kim, MD, medical oncologist, hematologist, Kaiser Permanente, discusses the feasibility of an assessment tool for older adults with cancer using web-based platforms.

Stefani Spranger on Î²-Catenin Signaling and Overcoming Immunotherapy Resistance

June 8th 2015

Stefani Spranger, PhD, University Chicago Melanoma Intrinsic Î²-Catenin Committee, discusses the effect of melanoma intrinsic Î²-catenin signaling on immune exclusion and resistance to immunotherapies.

Dr. Mesa on Pacritinib for Myelofibrosis

June 8th 2015

Ruben A. Mesa, MD, deputy director, Mayo Clinic, discusses PERSIST-1, a phase III study which examined pacribitinib as a treatment of myelofibrosis.

Dr. Tap on Olaratumab/Doxorubicin Combination in Soft Tissue Sarcomas

June 5th 2015

William Tap, MD, Medical Oncologist, Chief, Sarcoma Medical Oncology Service Memorial Sloan Kettering Cancer Center discusses the benefits of a olaratumab and doxorubicin combination treatment for advanced soft tissue sarcomas.

Dr. Philip McCarthy on Lenalidomide Maintenance for Multiple Myeloma

June 5th 2015

Philip McCarthy, MD, Professor of Oncology, Director, Blood and Marrow Transplant Center, Department of Medicine Roswell Park Cancer Institute, discusses the impact of the CALGB 100104 study which looked at lenalidomide maintenance following single autologous stem cell transplant for multiple myeloma.

Dr. Dung Le on Biomarker for PD-1 Agents in CRC

June 5th 2015

Dung T. Lee, MD, assistant professor of Oncology, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins Medicine, discusses a biomarker for PD-1 agents in colorectal cancer (CRC).

Dr. Manish Shah on the METGastric Study

June 4th 2015

Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the METGastric study.

Dr. Kader on PGS Stratifying Baseline Risk of Prostate Cancer in PLCO Trial

May 28th 2015

A. Karim Kader, MD, PhD, Minimally Invasive Surgery, Urology, Department of Surgery, University of California San Diego School of Medicine, discusses how prostate genetic score (PGS) stratifies baseline risk of prostate cancer and improves prostate-specific antigen (PSA) performance in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening trial.

Dr. Petrylak on the Future Immunotherapy in Bladder Cancer

May 27th 2015

Daniel Petrylak, MD, Professor of Medicine and of Urology; Professor, Signal Transduction Research Program at Yale Cancer Center discusses the future of immunotherapy in bladder cancer.

Dr. Deininger on the Role of Genetic Instability in Mutations That Lead to Cancer

May 27th 2015

Prescott Deininger, PhD, Professor and Regents Distinguished Chair, director, Tulane Cancer Center, Department of Epidemiology, Tulane University School of Public Health and Tropical Medicine, discusses how genetic instability plays a role in mutations that may lead to specific tumor types.

Dr. Mathew Hall on the Impact of PSA Screening Recommendations

May 27th 2015

Mathew Hall, MD, radiation oncologist, City of Hope National Medical Center, discusses the impact of prostate-specific antigen (PSA) screening recommendations.

Dr. Wierda on Ibrutinib Resistance in CLL

May 26th 2015

William G. Wierda, MD, PhD, medical director, Leukemia Center, The University of Texas MD Anderson Cancer Center, discusses resistance to ibrutinib in patients with chronic lymphocytic leukemia (CLL).